-
. You will have opportunities to analyze large-scale germline genotyping data, as well as tumor whole-genome sequencing data from childhood leukemia patients to investigate the etiologic role of early
-
patients with blood cancer, such as Multiple Myeloma. Our laboratory is part of the Judy & Bernard Briskin Center for Multiple Myeloma Research. We collaborate closely with clinicians who treat patients and
-
and progression, using a combination of mouse models, patient-derived samples, and high-throughput technologies, including next-generation sequencing, flow cytometry, and immunohistochemistry
-
innovative high-throughput sequencing technologies, bioinformatics approaches, and multi-scale models to elucidate RNA-mediated endothelial biology in the context of diabetes. Dr. Chen is passionate about
-
an active research program focused on epigenetics, RNA and chromatin biology and endothelial stress response. Her team integrates innovative high-throughput sequencing technologies, bioinformatics approaches
-
computational approaches, to decode tumor and immune biology and usher in a new era of biologically informed clinical care for patients with blood cancer, such as Multiple Myeloma. Our laboratory is part of
-
cell transplantation models, mouse genetics, molecular biology, biochemistry and cell biology, chemical biology, immunology, functional genomics, signal transduction, single-cell sequencing, spatial
-
functions of driver genetic lesions in high-risk leukemia subtypes. Perform high-throughput sequencing-based assays to systematically characterize leukemic and normal hematopoietic cells. Interpret multi
-
Cancer Journal (2022), Cell Stem Cell (2018). The Li research program is supported by multiple NIH (R01s), American Cancer Society, The Alex’s Lemonade Stand Foundation and several other prestigious
-
a wide range of studies, including transcriptomic, epigenomic, proteomic, T-cell receptor rearrangement sequencing, high dimensional spectral flow cytometry, in vitro organoid, and in vivo